4.5 Article

Studies on the spread of local anaesthetic solution in transversus abdominis plane blocks

Journal

ANAESTHESIA
Volume 66, Issue 11, Pages 1023-1030

Publisher

WILEY-BLACKWELL
DOI: 10.1111/j.1365-2044.2011.06855.x

Keywords

-

Categories

Ask authors/readers for more resources

The extent of analgesia provided by transversus abdominis plane blocks depends upon the site of injection and pattern of spread within the plane. There are currently a number of ultrasound-guided approaches in use, including an anterior oblique-subcostal approach, a mid-axillary approach and a more recently proposed posterior approach. We wished to determine whether the site of injection of local anaesthetic into the transversus abdominis plane affects the spread of the local anaesthetic within that plane, by studying the spread of a local anaesthetic and contrast solution in four groups of volunteers. The first group underwent the classical landmark-based transversus abdominis plane block whereby two different volumes of injectate were studied: 0.3 ml.kg(-1) vs 0.6 ml.kg(-1). The second group underwent transversus abdominis plane block using the anterior subcostal approach. The third group underwent transversus abdominis plane block using the mid-axillary approach. The fourth group underwent transversus abdominis plane block using the posterior approach, in which local anaesthetic was deposited close to the antero-lateral border of the quadratus lumborum. All volunteers subsequently underwent magnetic resonance imaging at 1, 2 and 4 h following each block to determine the spread of local anaesthetic over time. The studies demonstrated that the anterior subcostal and mid-axillary ultrasound approaches resulted in a predominantly anterior spread of the contrast solution within the transversus abdominis plane and relatively little posterior spread. There was no spread to the paravertebral space with the anterior subcostal approach. The mid-axillary transversus abdominis plane block gave faint contrast enhancement in the paravertebral space at T12-L2. In contrast, the posterior approaches, using both landmark and ultrasound identifications, resulted in predominantly posterior spread of contrast around the quadratus lumborum to the paravertebral space from T5 to L1 vertebral levels. We concluded that the pattern of spread of local anaesthetic differs depending on the site of injection into the transversus abdominis plane. This may have important implications for the extent of analgesia produced with each approach.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Critical Care Medicine

Reply to Leisman and Crowley

Vincenzo Russotto, Giacomo Bellani, John G. Laffey

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

Letter Anesthesiology

Airway pressure release ventilation: a survey of UK practice

Louise Rose, Luigi Camporota, Gary H. Mills, John Laffey, Gavin D. Perkins, Manu Shankar-Hari, Tamas Szakmany, Danny McAuley, RELEASE Investigators

BRITISH JOURNAL OF ANAESTHESIA (2023)

Article Engineering, Industrial

The development and preliminary evaluation of a clinician e-learning training platform for a neonatal sepsis risk monitor for use in ICU settings

Evismar Andrade, Leo R. Quinlan, Richard Harte, Bronwyn Reid-McDermott, Frank Kirrane, Enda Fallon, Martina Kelly, Tony Hall, Michael Scully, John Laffey, Patrick Pladys, Ethel Ryan, Dara Byrne, Gearoid OLaighin

Summary: This study developed an online training platform to train clinicians on the use of a critical care medical device and carried out a preliminary evaluation of the platform via a case study. The results showed that participants were able to use and interpret the device interface and were overall satisfied with the training platform, perceiving it as an efficient and effective method for training.

APPLIED ERGONOMICS (2023)

Article Multidisciplinary Sciences

A new multiplex SARS-CoV-2 antigen microarray showed correlation of IgG, IgA, and IgM antibodies from patients with COVID-19 disease severity and maintenance of relative IgA and IgM antigen binding over time

Marie Le Berre, Terezia Paulovcakova, Carolina De Marco Verissimo, Sean Doyle, John P. Dalton, Claire Masterson, Eduardo Ribes Martinez, Laura Walsh, Conor Gormley, John G. Laffey, Bairbre McNicholas, Andrew J. Simpkin, Michelle Kilcoyne

Summary: Zoonotic spillover of SARS-CoV-2 to humans in December 2019 caused the COVID-19 pandemic. Serological monitoring is crucial for understanding immune responses and guiding therapeutic and vaccine strategies. Researchers developed a high throughput SARS-CoV-2 antigen microarray for assessing IgG, IgA, and IgM responses, which can be used for expanded humoral immunity studies and monoclonal antibody therapeutic studies.

PLOS ONE (2023)

Article Biochemistry & Molecular Biology

Aerosolized Pulmonary Delivery of mRNA Constructs Attenuates Severity of Escherichia coli Pneumonia in the Rat

Sean D. McCarthy, Christopher B. Rohde, Matt Angel, Claire H. Masterson, Ronan MacLoughlin, Juan Fandino, Hector E. Gonzalez, Declan Byrnes, John G. Laffey, Daniel O'Toole

Summary: ARDS is a rapid-onset inflammatory lung disease without effective specific therapy, for which pneumonia is a common pathogenic etiology. Previous studies have shown that prophylactic delivery of mRNA coding for NF-kappa B inhibitor alpha super-repressor (I kappa B alpha-SR) or extracellular superoxide dismutase 3 (SOD3) by viral vector can help reduce the severity of pneumonia. This study demonstrates that nebulized mRNA therapeutics, complexed with cationic lipid and delivered through a vibrating mesh nebulizer, have potential as a promising approach for ARDS therapy. The mRNA treatments resulted in rapid expression of proteins and observable improvement in pneumonia symptoms.

NUCLEIC ACID THERAPEUTICS (2023)

Article Cell & Tissue Engineering

Nebulised mesenchymal stem cell derived extracellular vesicles ameliorate E. coli induced pneumonia in a rodent model

Hector Gonzalez, Sean McCarthy, Claire Masterson, Declan Byrnes, Ignacio Sallent, Emma Horan, Stephen J. Elliman, Gabriele Vella, Adriele P. Mello, Johnatas D. Silva, Anna D. Krasnodembskaya, Ronan MacLoughlin, John G. Laffey, Daniel O'Toole

Summary: In this study, the therapeutic potential of directly nebulised MSC-EVs in mitigating Escherichiacoli-induced pneumonia was investigated. The results showed that MSC-EVs retained their immunomodulatory and wound healing capacity after nebulisation. Treatment with IV or nebulised MSC-EVs reduced the severity of LPS-induced lung injury and E. coli-induced pneumonia.

STEM CELL RESEARCH & THERAPY (2023)

Letter Critical Care Medicine

WEAN SAFE and the definition of the first separation attempt

Tai Pham, Leo Heunks, Giacomo Bellani, Laurent Brochard, John Laffey

LANCET RESPIRATORY MEDICINE (2023)

Article Critical Care Medicine

Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, aTREM-1 inhibitor, in patients with septic shock (ASTONISH) : a double-blind, randomised, controlled, phase 2b trial

Bruno Francois, Simon Lambden, Tom Fivez, Sebastien Gibot, Marc Derive, Jean-Marie Grouin, Margarita Salcedo-Magguilli, Jeremie Lemarie, Nicolas De Schryver, Ville Jalkanen, Tarik Hicheur, Jean-Jacques Garaud, Valerie Cuvier, Ricard Ferrer, Morten Bestle, Ville Pettila, Jean-Paul Mira, Camille Bouisse, Emmanuelle Mercier, Joris Vermassen, Vincent Huberlant, Isabelle Vinatier, Nadia Anguel, Mitchell Levy, Pierre-Francois Laterre

Summary: This study aimed to investigate whether the TREM-1 inhibitor nangibotide could improve outcomes in patients with septic shock. The findings suggest that both low and high doses of nangibotide did not significantly improve the condition of patients with septic shock compared to placebo.

LANCET RESPIRATORY MEDICINE (2023)

Article Respiratory System

Awake prone positioning in acute hypoxaemic respiratory failure

Bairbre A. McNicholas, Miguel Ibarra-Estrada, Yonatan Perez, Jie Li, Ivan Pavlov, Aileen Kharat, David L. Vines, Oriol Roca, David Cosgrave, Claude Guerin, Stephan Ehrmann, John G. Laffey

Summary: Awake prone positioning (APP) gained attention during the COVID-19 pandemic for treating acute hypoxaemic respiratory failure. It improves oxygenation and has similar effects as invasive ventilation in patients with moderate-severe acute respiratory distress syndrome. Randomised controlled studies in COVID-19 patients have conflicting outcomes, but evidence suggests that more severe hypoxaemic patients benefit most from APP when managed in higher care environments and being prone for several hours.

EUROPEAN RESPIRATORY REVIEW (2023)

Article Medicine, General & Internal

Nebulized mesenchymal stem cell derived conditioned medium ameliorates Escherichia coli induced pneumonia in a rat model

Hector E. Gonzalez, Sean D. McCarthy, Claire Masterson, John G. Laffey, Ronan MacLoughlin, Daniel O'Toole

Summary: Mesenchymal stem cell secretome has strong immunomodulatory effects and can be delivered to the lung through nebulization, showing therapeutic potential for inflammatory diseases such as pneumonia ARDS.

FRONTIERS IN MEDICINE (2023)

Article Respiratory System

Estimating the attributable fraction of mortality from acute respiratory distress syndrome to inform enrichment in future randomised clinical trials

Rohit Saha, Tai Pham, Pratik Sinha, Manoj Maddali, Giacomo Bellani, Eddy Fan, Charlotte Summers, Abdel Douiri, Gordon D. Rubenfeld, Carolyn S. Calfee, John Gerard Laffey, Daniel Francis McAuley, Manu Shankar-Hari, LUNG SAFE Investigators

Summary: This study estimated the mortality rate of acute respiratory distress syndrome (ARDS) using a case-control matching method and analyzed it in different patient subgroups. The results showed that there were variations in the mortality rate of ARDS among different subgroups. Depending on the severity of hypoxemia, the number of lung quadrants involved, and the inflammatory phenotype, the mortality rate of ARDS ranged from 20.9% to 38.0%.

THORAX (2023)

Article Anesthesiology

Development and assessment of the performance of a shared ventilatory system that uses clinically available components to individualize tidal volumes

David M. Hannon, Tim Jones, Jack Conolly, Conor Judge, Talha Iqbal, Atif Shahzad, Michael Madden, Frank Kirrane, Peter Conneely, Brian H. Harte, Martin O'Halloran, John G. Laffey

Summary: Developed and assessed a system for shared ventilation using clinically available components to individualize tidal volumes. The system allowed accurate and reproducible titration of tidal volumes to each limb over a range of ventilator settings and simulated lung conditions.

BMC ANESTHESIOLOGY (2023)

Article Critical Care Medicine

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

Marius Troseid, Jose R. Arribas, Lambert Assoumou, Aleksander Rygh Holten, Julien Poissy, Vida Terzic, Fulvia Mazzaferri, Jesus Rodriguez Bano, Joe Eustace, Maya Hites, Michael Joannidis, Jose-Artur Paiva, Jean Reuter, Isabel Puentmann, Thale D. J. H. Patrick-Brown, Elin Westerheim, Katerina Nezvalova-Henriksen, Lydie Beniguel, Tuva Borresdatter Dahl, Maude Bouscambert, Monika Halanova, Zoltan Peterfi, Sotirios Tsiodras, Michael Rezek, Matthias Briel, Serhat Unal, Martin Schlegel, Florence Ader, Karine Lacombe, Cecilie Delphin Amdal, Serge Rodrigues, Kristian Tonby, Alexandre Gaudet, Lars Heggelund, Joy Mootien, Asgeir Johannessen, Jannicke Horjen Moller, Beatriz Diaz Pollan, Anders Aune Tveita, Anders Benjamin Kildal, Jean-Christophe Richard, Olav Dalgard, Victoria Charlotte Simensen, Aliou Balde, Lucie de Gastines, Marta del Alamo, Burc Aydin, Fridtjof Lund-Johansen, Mary-Anne Trabaud, Alpha Diallo, Bente Halvorsen, John-Arne Rottingen, Evelina Tacconelli, Yazdan Yazdanpanah, Inge C. Olsen, Dominique Costagliola

Summary: The study conducted a placebo-controlled trial of baricitinib in severe/critical COVID cases. The results showed that baricitinib did not reduce mortality within 60 days, and there may be safety risks in vaccinated participants, which require further investigation.

CRITICAL CARE (2023)

Meeting Abstract Critical Care Medicine

PRONE POSITIONING FOR NONINTUBATED COVID-19 PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Jie Li, Jian Luo, Ivan Pavlov, Yonatan Perez, Aileen Kharat, Elsa Tavernier, David Vines, Oriol Roca, Bairbre McNicholas, Miguel Ibarra-Estrada, John Laffey, Claude Guerin, Stephan Ehrmann

CRITICAL CARE MEDICINE (2023)

Article Critical Care Medicine

Epidemiology and outcomes of early-onset AKI in COVID-19-related ARDS in comparison with non-COVID-19-related ARDS: insights from two prospective global cohort studies

Bairbre A. A. McNicholas, Emanuele Rezoagli, Andrew J. J. Simpkin, Sankalp Khanna, Jacky Y. Y. Suen, Pauline Yeung, Daniel Brodie, Gianluigi Li Bassi, Tai Pham, Giacomo Bellani, John F. F. Fraser, John Laffey

Summary: AKI is a common and serious complication in COVID-19 patients, with different characteristics and outcomes compared to non-COVID-19 ARDS patients.

CRITICAL CARE (2023)

No Data Available